Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Marcus Weldon (NPI 1942689286)

Field	Value
Entity Type	Individual
Organization	Marcus Weldon
Address	800 1st St Ste 410
City	Macon
State	GA
ZIP	31201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 19, 2015

Payer Source	Total Paid
Medicare	$2.5M
Medicaid	$0

Key Findings

Service mix is concentrated in outpatient oncology infusion and high-cost monoclonal antibody therapy: the provider’s top revenue drivers are J9271, J9144, and J9299 (pembrolizumab, daratumumab, and nivolumab), and the claims list includes multiple chemotherapy administration codes (96413, 96365, 96367, 96417), which together indicate an on-site infusion practice treating Medicare oncology patients with immunotherapy and multi-agent regimens. The presence of lab and supportive care codes (85025, 80053, 82728, J0885) further supports a full-service oncology/hematology clinic model rather than a strictly consultative practice.

Revenue is highly concentrated in a few drugs: the precomputed top-3 codes account for 66.2% of the provider’s Medicare revenue, with J9271 at $894.4K (36.7% of total Medicare revenue), J9144 at $459.5K (18.9%), and J9299 at $258.2K (10.6%). These three agents alone represent the majority of the reported $2.5M in Medicare revenue, underscoring dependence on a small set of high-cost oncology biologics.

This provider is effectively single-payer at the claim level: Medicare revenue is $2.5M while there is no Medicaid billing on file, so analyses of utilization, access, and financial risk should treat the practice as Medicare-focused rather than mixed Medicaid/Medicare. The absence of Medicaid activity also suggests the patient mix and contracting dynamics observed in Medicare will dominate any payer-negotiation or network-access workstreams.

Competitive standing on key immunotherapies is mixed: J9271 (pembrolizumab) reports $894.4K and ranks #358 of 1841 providers nationally (80th percentile; typical, unremarkable volume for this code), and J9144 (daratumumab) reports $459.5K and ranks #139 of 615 (77th percentile; typical, unremarkable volume). By contrast J9299 (nivolumab) is smaller at $258.2K and ranks #334 of 505 providers (34th percentile; typical, unremarkable volume), indicating the provider has relatively stronger activity in pembrolizumab and daratumumab than in nivolumab compared with national peers.

The provider’s office visit mix shows an unusual concentration at higher-complexity outpatient E/M: 99214 generated 1.4K claims and $128.4K (5.3% of Medicare revenue) and is described as an "extreme outlier, far above typical national volume for this code" (ranks #4200 of 479517, 99th percentile). This elevated level-4 E/M volume suggests substantial ongoing follow-up and management workload for established patients, consistent with repetitive infusion cycles and complex care coordination.

Chemotherapy administration volumes are above typical in several administration codes: 96413 shows 644 claims for $59.2K and is reported as "notably above typical national volume" (ranks #337 of 7514, 95th percentile), while additional infusion/add-on codes (96365, 96367, 96417) also sit at high national percentiles. Together these administration-code patterns corroborate a busy infusion clinic capable of delivering multiple infusions per patient and handling extended or sequential infusion regimens.

The practice uses biosimilars and supportive agents alongside originator biologics, which is visible in the J/Q-code mix: Q5119 (rituximab biosimilar ruxience) contributed $67.2K (2.8%), Q5107 (bevacizumab biosimilar mvasi) $46.6K (1.9%), and Q5111 (pegfilgrastim biosimilar udenyca) $27.5K (1.1%). J0897 denosumab appears as a meaningful supportive/immunomodulatory therapy with $186.8K (7.7% of Medicare revenue) and ranks #1076 of 10057 (89th percentile; typical, unremarkable volume), suggesting standard supportive-care protocols are in use alongside specialty oncology infusions.

Tenure and operational maturity are consistent with an established outpatient oncology provider: the NPI was enumerated 2015-05-19 (~11 years ago), which aligns with the scale of Medicare billing ($2.5M) and the breadth of infusion and E/M activity reported. For payers and competitors, this tenure plus the single-payer Medicare concentration implies a stable Medicare-facing referral footprint and predictable revenue exposure tied to high-cost oncology biologics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

82 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,800	$40	$894.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	12,420	$40	$459.5K
J9299	Injection, nivolumab, 1 mg	10,760	$20	$258.2K
J0897	Injection, denosumab, 1 mg	10,380	$20	$186.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,430	$90	$128.4K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,060	$20	$67.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	640	$90	$59.2K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	5,300	$10	$53K
J1439	Injection, ferric carboxymaltose, 1 mg	50,250	$1	$50.3K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	2,030	$20	$46.6K

Showing 1–10 of 82

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 82 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Marcus Weldon — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

82 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	40	15,200	$40	$767.3K
J9299	8	10	15,910	$20	$431.3K
J9144	2	10	9,450	$40	$321.2K
J0897	37	290	2,460	$20	$90.2K
Q5107	6	10	3,280	$20	$69.8K
J9264	2	10	5,880	$10	$58.8K
Q5119	1	10	2,140	$20	$46.8K
J1439	6	30	28,130	$1	$32.3K
Q5111	3	10	270	$110	$28.8K
J0885	7	30	3,970	$10	$26.6K

Showing 1–10 of 82

Related Providers

Other providers that share a Tax Identification Number (TIN) with Marcus Weldon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Robert Muldoon	AR	Hematology & Oncology Physician	$3.2M	$0
Bradley Sumrall	GA	Medical Oncology Physician	$3.1M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Marcus Weldon, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Health Services Of Central Georgia, Inc	GA	Multi-Specialty Clinic/Center	$0	$18.5M
Central Georgia Emergency Group, LLC	GA	Emergency Medicine Physician	$0	$8.8M
Middle Georgia Pediatrics	GA	Pediatric Adolescent Medicine Physician	$0	$4.2M
Mgas Holdings, LLC	GA	Ambulance	$2.5M	$36.9K
Cogent Healthcare Of Macon, LLC	GA	Internal Medicine Physician	$0	$1.8M
Central Georgia Pediatrics, Inc.	GA	Pediatric Adolescent Medicine Physician	$0	$1.6M
Alan Justice	GA	Internal Medicine Physician	$1.4M	$0
Central Georgia Pet LLC	GA	Radiation Oncology Physician	$1.4M	$0
Children's Neurology Ctr Macon, LLC	GA	Neurology with Special Qualifications in Child Neurology Physician	$0	$1.3M
Central Georgia Radiation Oncology Center	GA	Radiation Oncology Physician	$0	$1.1M

Marcus Weldon — Billing Profile & Reimbursement Data

Sign up for Marcus Weldon — Billing Profile & Reimbursement Data policy alerts

Marcus Weldon — Billing Profile & Reimbursement Data

Sign up for Marcus Weldon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References